IGM Biosciences Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 OR IGM Biosciences, Inc. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the Registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of July 25, 2025, the registrant had36,593,204shares of common stock, $0.01 par value per share, and23,699,483sharesof non-voting common stock, $0.01 par value per share, outstanding. 1IGM Biosciences, Inc. (the “Registrant”) terminated its lease agreements for all existing office space. Accordingly, the Registrantdoes not maintain headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, asamended, and Securities Act of 1934, as amended, any stockholder communication required to be sent to the Registrant’s principalexecutive offices may be directed to IGM Biosciences, Inc.,3 East Third Avenue,Suite 200,San Mateo,CA94401. Table ofContents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Condensed Balance SheetsCondensed Statements of OperationsCondensed Statements of Comprehensive Income (Loss)Condensed Statements of Stockholders’ EquityCondensed Statements of Cash FlowsNotes to Unaudited Condensed Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures Special Note Regarding Forward Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical factscontained in this report are forward-looking statements. These statements involve known and unknown risks, uncertainties, andother important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements tobe materially different from any future results, performance, or achievements expressed or implied by the forward-lookingstatements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,” “continue,”“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or“would,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Reporton Form 10-Q include, but are not limited to, statements about: our ability to successfully consummate the transactioncontemplated pursuant to the Merger Agreement (defined below) or, if we are not successful in consummating such transaction, ourability to successfully identify and implement any other strategic alternative; the expected timing of the closing of the transactioncontemplated pursuant to the Merger Agreement; the implementation of our strategic plans, including our expectations regardingthe 2024 Restructuring (defined below) the January 2025 Restructuring (defined below), and the April 2025 Restructuring (definedbelow); our expectations regarding the impact of macroeconomic conditions, such as inflation, supply chain disruptions andeconomic volatility; our expectations regarding the impact of health epidemics, such as the COVID-19 pandemic, and othercatastrophic events; our anticipated use of our e